UBS Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $930M | Sell |
14,824,662
-47,464
| -0.3% | -$3.8M | 0.14% | 145 |
|
|
2025
Q4 | $1.42B | Buy |
14,872,126
+4,304,984
| +41% | +$422M | 0.23% | 67 |
|
|
2025
Q3 | $1.03B | Sell |
10,567,142
-937,523
| -8% | -$97.1M | 0.16% | 102 |
|
|
2025
Q2 | $1.24B | Buy |
11,504,665
+2,224,498
| +24% | +$225M | 0.21% | 79 |
|
|
2025
Q1 | $936M | Buy |
9,280,167
+16,536
| +0.2% | +$1.67M | 0.17% | 100 |
|
|
2024
Q4 | $827M | Buy |
9,263,631
+1,491,819
| +19% | +$131M | 0.15% | 126 |
|
|
2024
Q3 | $651M | Buy |
7,771,812
+631,888
| +9% | +$49.8M | 0.14% | 133 |
|
|
2024
Q2 | $550M | Sell |
7,139,924
-638,461
| -8% | -$46.7M | 0.14% | 140 |
|
|
2024
Q1 | $533M | Buy |
7,778,385
+726,746
| +10% | +$46.7M | 0.13% | 148 |
|
|
2023
Q4 | $408M | Buy |
7,051,639
+1,531,625
| +28% | +$81.8M | 0.12% | 168 |
|
|
2023
Q3 | $291M | Sell |
5,520,014
-197,537
| -3% | -$10.4M | 0.1% | 202 |
|
|
2023
Q2 | $309M | Buy |
5,717,551
+43,643
| +0.8% | +$2.28M | 0.1% | 197 |
|
|
2023
Q1 | $284M | Sell |
5,673,908
-251,847
| -4% | -$11.9M | 0.1% | 197 |
|
|
2022
Q4 | $274M | Buy |
5,925,755
+756,716
| +15% | +$32.8M | 0.1% | 207 |
|
|
2022
Q3 | $200M | Sell |
5,169,039
-334,078
| -6% | -$13.4M | 0.09% | 235 |
|
|
2022
Q2 | $205M | Sell |
5,503,117
-12,903
| -0.2% | -$525K | 0.08% | 256 |
|
|
2022
Q1 | $244M | Buy |
5,516,020
+205,393
| +4% | +$8.9M | 0.08% | 251 |
|
|
2021
Q4 | $226M | Buy |
5,310,627
+548,414
| +12% | +$23M | 0.06% | 309 |
|
|
2021
Q3 | $207M | Buy |
4,762,213
+488,690
| +11% | +$21.6M | 0.07% | 292 |
|
|
2021
Q2 | $183M | Buy |
4,273,523
+897,913
| +27% | +$37.8M | 0.06% | 324 |
|
|
2021
Q1 | $130M | Buy |
3,375,610
+1,995,916
| +145% | +$75.5M | 0.04% | 408 |
|
|
2020
Q4 | $49.6M | Sell |
1,379,694
-226,933
| -14% | -$8.18M | 0.02% | 792 |
|
|
2020
Q3 | $61.4M | Sell |
1,606,627
-290,837
| -15% | -$11.2M | 0.02% | 568 |
|
|
2020
Q2 | $66.6M | Buy |
1,897,464
+396,890
| +26% | +$14.3M | 0.03% | 491 |
|
|
2020
Q1 | $49M | Sell |
1,500,574
-561,849
| -27% | -$21.9M | 0.02% | 548 |
|
|
2019
Q4 | $93.3M | Sell |
2,062,423
-322,119
| -14% | -$13.5M | 0.03% | 474 |
|
|
2019
Q3 | $97M | Buy |
2,384,542
+80,524
| +3% | +$3.41M | 0.04% | 418 |
|
|
2019
Q2 | $99M | Sell |
2,304,018
-96,278
| -4% | -$3.7M | 0.04% | 401 |
|
|
2019
Q1 | $92.1M | Buy |
2,400,296
+440,812
| +22% | +$16.8M | 0.04% | 407 |
|
|
2018
Q4 | $69.2M | Sell |
1,959,484
-200,690
| -9% | -$7.28M | 0.03% | 471 |
|
|
2018
Q3 | $83.2M | Buy |
2,160,174
+287,614
| +15% | +$10M | 0.03% | 468 |
|
|
2018
Q2 | $61.2M | Buy |
1,872,560
+787,397
| +73% | +$23.7M | 0.03% | 559 |
|
|
2018
Q1 | $29.6M | Sell |
1,085,163
-25,307
| -2% | -$688K | 0.01% | 907 |
|
|
2017
Q4 | $27.5M | Sell |
1,110,470
-300,329
| -21% | -$8.28M | 0.01% | 983 |
|
|
2017
Q3 | $41.2M | Sell |
1,410,799
-179,440
| -11% | -$4.96M | 0.02% | 695 |
|
|
2017
Q2 | $44.1M | Buy |
1,590,239
+237,094
| +18% | +$6.29M | 0.02% | 616 |
|
|
2017
Q1 | $33.7M | Buy |
1,353,145
+192,357
| +17% | +$4.68M | 0.02% | 725 |
|
|
2016
Q4 | $25.1M | Sell |
1,160,788
-115,641
| -9% | -$2.52M | 0.01% | 891 |
|
|
2016
Q3 | $30.4M | Buy |
1,276,429
+498,061
| +64% | +$11.9M | 0.02% | 728 |
|
|
2016
Q2 | $18.2M | Buy |
778,368
+158,325
| +26% | +$3.43M | 0.01% | 989 |
|
|
2016
Q1 | $11.7M | Sell |
620,043
-441,584
| -42% | -$7.76M | 0.01% | 1226 |
|
|
2015
Q4 | $19.6M | Buy |
1,061,627
+300,642
| +40% | +$5.39M | 0.01% | 971 |
|
|
2015
Q3 | $12.5M | Sell |
760,985
-71,503
| -9% | -$1.22M | 0.01% | 1213 |
|
|
2015
Q2 | $14.7M | Sell |
832,488
-28,830
| -3% | -$515K | 0.01% | 1184 |
|
|
2015
Q1 | $15.3M | Sell |
861,318
-251,310
| -23% | -$3.97M | 0.01% | 1144 |
|
|
2014
Q4 | $14.7M | Buy |
+1,112,628
| New | +$14.2M | 0.01% | 1205 |
|
Other funds holding BSX
VCM
VPM
UBS Group's BSX Position: Q1 2026 in Review
UBS Group reduced its Boston Scientific (BSX) stake by 0.32% in Q1 2026, selling an estimated $3.8M and leaving 14,824,662 shares worth $930M. The position accounts for 0.14% of the portfolio, ranked #145.
UBS Group first reported a position in BSX in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.42B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- UBS Group held 14,824,662 shares of Boston Scientific worth $930M as of Q1 2026.
- UBS Group sold 47,464 Boston Scientific shares in Q1 2026, an estimated $3.8M.
- Boston Scientific made up 0.14% of UBS Group's portfolio in Q1 2026, its #145 holding.
- UBS Group first reported a position in Boston Scientific in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Boston Scientific position peaked at $1.42B in Q4 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.